期刊文献+

静滴丙氨酰谷氨酰胺减少FOLFOX4方案的不良反应 被引量:6

Application of parenteral supplemented with Ala-Gln in patients with gastrointestinal neoplasms could reduce the side effects induced by FOLFOX4
下载PDF
导出
摘要 目的研究化疗期间静滴丙氨酰谷氨酰胺是否能减少FOLFOX4方案的不良反应。方法晚期胃癌和肠癌患者84例随机分为FOLFOX4方案加静脉滴注丙氨酰谷氨酰胺组(治疗组)和单纯FOLFOX4方案组(对照组),每组42例,观察两组的疗效和不良反应。结果两组的化疗有效率无显著差异(P>0.05);化疗两周期后,治疗组的Ⅰ~Ⅱ度神经毒性显著降低(P<0.05),两组均未见Ⅲ度以上神经毒性;化疗四周期后,治疗组Ⅰ~Ⅱ度和Ⅱ~Ⅳ度神经毒性发生率分别为23.8%和4.8%,明显少于对照组的40.5%和19.0%(P<0.05);治疗组腹泻发生率为7.1%,明显低于对照组和26.2%(P<0.05);两组口腔黏膜炎的发生率未见明显差异(P>0.05)。结论使用FOLFOX4方案的同时使用静脉输注丙氨酰谷氨酰胺不仅不影响疗效,而且能够减少该方案的不良反应。
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2011年第6期486-488,共3页 Chinese Journal of Biochemical Pharmaceutics
  • 相关文献

二级参考文献5

  • 1Goldberg R, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J]. J Clin Oncol, 2004,22 (1):23-30.
  • 2Cheeseman S, Joel S, Chester J, et al. A "modified de gramont" regimen of fluorouracil, alone and with oxaliplatin,for advanced colorectal cancer [J]. Brit J Cancer, 2002,87:393-399.
  • 3Douillard J, Cunning, ham D, Roth A, et al. Irinotecan combined with fluorouraeil compared with fluorouraeil alone as first-line treatment for metastatic colorectal cancer:a muhicentre randomised trial [J]. The Lancet, 2000,355: 1041-1047.
  • 4Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11(irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer [J]. Eur J Cancer, 1999,35(9): 1343-1347.
  • 5Maindrauh-Groebel F, Lledo G, Chibaudel B, et al.OPTIMOX2, a large randomized phase Ⅱ study of maintenance therapy or chemotherapy-free interval (CF1) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study[J]. 2006 ASCO Annual Meeting Proceedings, Abstract 3504.

共引文献46

同被引文献89

  • 1黄思玲,边玲.中国药典2010年版生化药物简介[J].食品与药品,2011,13(5):219-222. 被引量:3
  • 2何昌谋,郭雄.膝关节腔注射透明质酸钠对成人大骨节病血清透明质酸、CD44、硫酸角质素含量的影响[J].中华临床医师杂志(电子版),2011,5(16):4852-4854. 被引量:3
  • 3李海金,董良,李英.还原型谷胱甘肽预防奥沙利铂神经毒性疗效观察[J].全科医学临床与教育,2007,5(5):387-388. 被引量:7
  • 4Yue C, Tian WL, Wang W, et al. The impact of perioperative gluta- mine-supplemented parenteml nutrition on outcomes of patients un- dergoing abdominal surgery : A meta-analysis of randomized clinical trials [ J]. Am Surg,2013,79 ( 5 ) :506 - 513.
  • 5国家食品药品监督管理局药品审评中心;四川美康医药软件研究开发有限公司.药物临床信息参考[M]成都:四川科学技术出版社,2004622.
  • 6Chang FY,Lu CL. Irritable bowel syndrome in the 21sr century:perspectives from Asia or South-east Asia[J].Journal of Gastroenterology and Hepatology,2007,(01):4-12.
  • 7CUI S,HU Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebocontrolled study[J].lnt J Clin Exp Med,2012,(03):238-244.
  • 8Guglielmetii S,Mora G,schwender M. Randomised clinical trial:Bifidobocteriuni bifulum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind,placebo-controlled study[J].Alimentary Pharmacology and Therapeutics,2011,(10):1123-1132.
  • 9KiChaB,Mun Jung S,Hwan Choi C. The effect of a nulti species probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome a randomized,doubleblind,placebo-controlled trial[J].Journal of Clinical Gastroenterology,2012,(03):220-227.
  • 10李明颖,徐建明,宋三泰,程建鹏.钙镁合剂防治草酸铂神经毒性的临床研究[J].肿瘤学杂志,2009,15(5):450-452. 被引量:5

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部